- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02808741
Evaluation of Immediate Release Tablet
F901318 - A Two Part Study Designed to Evaluate the Single and Multiple Dose Pharmacokinetics of an Immediate Release Tablet Formulation of F901318
Single dose comparison of liquid and solid formulation, followed by study of effect of high fat breakfast.
Evaluation of multiple dose pharmacokinetics and tolerability
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be split into 2 parts, Part 1, ( A and B), and Part 2.
Part 1A Part 1A of the study will be a single centre, open label, 2-way crossover in healthy male and female volunteers and will assess the relative bioavailability of a single 360 mg dose (as 3 x 120mg tablets) of F901318 IR tablet formulation in comparison to a 360 mg dose of an SDD suspension for oral dosing. It is planned that 10 volunteers will be enrolled to Part 1A of the study. These 10 subjects will continue into Part 1B of the study.
There will be a minimum washout of 10 days between doses provided to volunteers.
Following Part 1A there will be a two week period of interim analysis during which safety and pharmacokinetic data will be reviewed. In order to assess doses within the therapeutic range in Part 1B, a decision will be made using the available data, on whether the dose of F901318 IR tablet formulation should be altered. Dose will be altered by amending the number of units dosed.
Part 1B Following the dose decision meeting where data obtained in Part 1A of the study is reviewed, the selected dose of F901318 IR tablet formulation will be assessed in a further single centre, open label, 2-way crossover in healthy male and female volunteers. The selected dose will be administered in the fed (30 minutes following an FDA high fat meal) and fasted states in a randomised fashion. .
There will be a minimum washout of 10 days between doses provided to volunteers.
Following Part 1B there will period a period of interim analysis during which safety and pharmacokinetic data will be reviewed. In order to assess doses within the therapeutic range in Part 2, a decision will be made using the available data, on the dose of F901318 IR formulation to be dosed in Part 2. Dose will be altered by amending the number of units dosed. It will also be determined if doses in Part 2 will be administered in the fed or fasted state.
Part 2 In part 2, the dose(s) anticipated to yield therapeutic plasma concentrations will be tested over a 10-day period. This will be a double blind placebo controlled, randomised, parallel group design in 10 healthy male and female subjects, 8 taking active compound and 2 taking placebo. In order to mimic the expected treatment schedule in phase 2 trials, it is anticipated that there will be a loading dose given over 1 or 2 days, followed by once daily or twice daily doses of study drug up to a total of 10 days.
In both parts of the study, blood will be drawn for safety and pharmacokinetic evaluation. Adverse events, vital signs and 12 lead ECGs will be monitored throughout. In Part 1, Holter monitoring will be performed for 12 hours after each dose. Part 2, ECG Holter monitoring will be performed on Days 1 and 10 only.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Nottingham, United Kingdom
- Quotient Clinical
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects will be healthy males or females of any ethnic origin between 18 and 55 years of age and weighing between 50-100 kg (body mass index of 18.0-32.0 kg/m2 inclusive).
- Females of child bearing potential must be established on a reliable form of contraception and have a negative pregnancy test at screening.
- Subjects must be in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations (congenital non haemolytic hyperbilirubinaemia is acceptable).
- Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions.
Exclusion Criteria:
- Subjects who do not have suitable veins for multiple vene-punctures/cannulation as assessed by the investigator at screening
- Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator
- Male or female subjects who are not willing to use appropriate contraception during the study and until 3 months after the last dose.
- Subjects who have received any prescribed systemic or topical medication within 14 days of the dose administration unless in the opinion of the Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: F901318 SDD
Liquid formulation
|
Pharmacokinetics area under curve
|
EXPERIMENTAL: F901318 IR
Solid formulation
|
Pharmacokinetics area under curve
|
EXPERIMENTAL: F901318 IR Fasting
Fasting solid formulation
|
Pharmacokinetics area under curve
|
EXPERIMENTAL: F901318 IR Fed
Fed solid formulation
|
Pharmacokinetics area under curve
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics
Time Frame: 120 hours
|
Area Under Concentration Time Curve
|
120 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment emergent adverse events
Time Frame: 120 hours
|
Incidence of Treatment-Emergent Adverse Events [Safety]).
|
120 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F901318-01-07-16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Aspergillosis
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownInvasive Aspergillosis | Invasive Candidiasis
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingInvasive Aspergillosis | Invasive CandidiasisChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedPulmonary Invasive AspergillosisNetherlands
-
Melbourne HealthMerck Sharp & Dohme LLCRecruitingFungal Infection | Pharmacokinetics | Invasive Aspergillosis | Prophylaxis | Invasive Candidiases | Posaconazole | Invasive MycosisAustralia
-
Arkansas Children's Hospital Research InstituteNational Institute of Allergy and Infectious Diseases (NIAID); Children's Hospital...RecruitingPulmonary Invasive Fungal Infections | Pulmonary Invasive AspergillosisUnited States, Canada
-
Erasmus Medical CenterGilead SciencesCompletedAspergillosis, Invasive PulmonaryNetherlands
-
Astellas Pharma Global Development, Inc.CompletedInvasive Aspergillosis | Invasive MucormycosisUnited States, Belgium, Spain
-
VicalTerminatedInvasive Aspergillosis | Invasive Pulmonary AspergillosisUnited States, Korea, Republic of, Canada, Belgium, France, Germany
-
Imagine InstituteRecruitingInvasive Aspergillosis | Cerebral AspergillosisFrance
-
Astellas Pharma IncWithdrawnAspergillosis/Blood | Aspergillosis/InvasiveUnited States
Clinical Trials on F901318 SDD
-
Medicines for Malaria VentureAbbVieTerminatedHealthy Volunteers | BioavailabilityUnited States
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
NeuroTherapia, Inc.Integrium; Orange County Research CenterCompleted
-
Gilead SciencesTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Non-FL Indolent Non-Hodgkin's LymphomaUnited States, Canada
-
Medicines for Malaria VentureAbbVieCompleted
-
F2G Biotech GmbHSimbec-Orion GroupCompleted
-
F2G Biotech GmbHQuotient ClinicalWithdrawn
-
Radboud University Medical CenterUniversitaire Ziekenhuizen KU Leuven; ZonMw: The Netherlands Organisation for...Not yet recruiting
-
F2G Biotech GmbHCovanceCompletedInvasive AspergillosisUnited Kingdom
-
F2G Biotech GmbHCompletedHepatic ImpairmentUnited States